WO2023003223A1 - Eye treatment structure - Google Patents

Eye treatment structure Download PDF

Info

Publication number
WO2023003223A1
WO2023003223A1 PCT/KR2022/009708 KR2022009708W WO2023003223A1 WO 2023003223 A1 WO2023003223 A1 WO 2023003223A1 KR 2022009708 W KR2022009708 W KR 2022009708W WO 2023003223 A1 WO2023003223 A1 WO 2023003223A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug delivery
eyeball
drug
delivery unit
eye
Prior art date
Application number
PCT/KR2022/009708
Other languages
French (fr)
Korean (ko)
Inventor
나경선
전윤홍
Original Assignee
가톨릭대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가톨릭대학교 산학협력단 filed Critical 가톨릭대학교 산학협력단
Publication of WO2023003223A1 publication Critical patent/WO2023003223A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0008—Fixation appliances for connecting prostheses to the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir

Definitions

  • the disclosed technology relates to an eye treatment structure for continuously delivering a drug to the eye.
  • the disclosed technology is to provide a structure for ocular treatment for continuously delivering a drug to the eye.
  • the first aspect of the technology disclosed to achieve the above technical problem is an elliptical lens shape and is located on the surface of the wearer's eyeball to deliver a drug to the eyeball and a drug delivery unit formed along the edge of the drug delivery unit and erected at a certain height
  • An object of the present invention is to provide a structure for eye treatment including a plurality of support parts that keep the drug delivery unit from contacting the eyeball according to the body and are respectively fixed to the eyeball using grooves formed on the lower surface.
  • Embodiments of the disclosed technology may have effects including the following advantages. However, this does not mean that the embodiments of the disclosed technology must include all of them, so the scope of rights of the disclosed technology should not be understood as being limited thereby.
  • the structure for eye treatment according to an embodiment of the disclosed technology has an effect of reducing foreign body sensation by delivering a drug at a location spaced apart from the surface of the eye by a predetermined distance or more.
  • FIG. 1 is a perspective view showing a structure for eye treatment according to an embodiment of the disclosed technology.
  • FIG. 2 is a view showing a structure for eye treatment in the form of an open center.
  • FIG. 3 is a view showing a drug delivery unit in a planar shape.
  • FIG. 4 is a view showing a drug delivery unit in a curved shape.
  • 5 is a view showing that it is inserted and fixed to the conjunctival tissue.
  • first, second, A, B, etc. may be used to describe various components, but the components are not limited by the above terms, and are only used for the purpose of distinguishing one component from another.
  • a first element may be termed a second element, and similarly, a second element may be termed a first element, without departing from the scope of the present invention.
  • the terms and/or include any combination of a plurality of related recited items or any of a plurality of related recited items.
  • classification of components in the present specification is merely a classification for each main function in charge of each component. That is, two or more components to be described below may be combined into one component, or one component may be divided into two or more for each more subdivided function.
  • each component to be described below may additionally perform some or all of the functions of other components in addition to its main function, and some of the main functions of each component may be performed by other components. Of course, it may be dedicated and performed by . Therefore, the existence or nonexistence of each component described through this specification should be interpreted functionally.
  • the structure for eye treatment includes a drug delivery unit 110 and a plurality of support units 120 .
  • the drug delivery unit 110 has an oval lens shape. In general, it may be a transparent material like a lens worn on the eyeball.
  • the drug delivery unit is located on the surface of the wearer's eyeball to deliver the drug to the eyeball.
  • the drug delivery unit may have a structure with an open center so as not to obstruct the wearer's field of view. For example, the center may be empty like a donut shape.
  • the drug delivery unit may be formed of a biocompatible polymer material into which the drug is incorporated.
  • it may be formed in a state in which a drug is mixed with a material such as collagen or a drug is applied to the outer surface of the material.
  • the drug delivery unit may be formed by discharging the above-described biocompatible polymeric material by electrospinning.
  • a drug is applied to the surface facing the eyeball, and the drug delivery unit 110 is formed into a curved surface in a shape corresponding to the shape of the eyeball by the adhesive force formed by the drug, and can be attached thereto. there is.
  • the drug delivery unit 110 does not directly contact the eye, but may be indirectly attached to the eye through the drug.
  • a plurality of support units are formed along the edge of the drug delivery unit.
  • a plurality of support units may be formed at regular intervals at the edge of the drug delivery unit formed in an elliptical body.
  • the intervals of each support part may be equal intervals from each other or may be formed at predetermined positions.
  • Each of the support parts can keep the drug delivery part from contacting the eyeball according to the body erected at a certain height.
  • the body In the case of a lens-shaped structure worn by patients with visual problems, such as the conventional Artiflex, the body is in close contact with the surface of the eyeball, causing additional damage to the conjunctiva or worsening the foreign body sensation in the eye.
  • the bodies of the plurality of supporters are erected in a vertical direction to the drug delivery unit, so that the drug delivery unit and the surface of the eyeball can be maintained at a predetermined interval. Accordingly, the eyeball can be continuously exposed to the same amount of drug without feeling a foreign body sensation, so that the eyeball can be used without great discomfort even when used for a long time.
  • a groove 120a is formed on the lower surface of each of the plurality of support parts.
  • it is a method of fixing by suturing to one side of the eyeball or the conjunctiva itself, so additional conjunctival damage may occur. This method has the advantage of not causing additional conjunctival damage.
  • the space 201 at the center of the body of the drug delivery unit may have an empty structure so as not to obstruct the wearer's vision. That is, it is possible to further reduce discomfort by securing a field of view when worn. It is also possible to additionally administer a drug such as eye drops through an additionally empty space. In this case, as in the prior art, it is possible to prevent the drug from flowing out.
  • FIG. 3 is a view showing a drug delivery unit in a planar shape.
  • Figure 4 is a view showing a drug delivery unit in the form of a curved surface.
  • the drug delivery unit may have a flat surface or a curved surface like a conventional lens, depending on the user's needs or eye conditions.
  • FIG. 5 is a view showing that it is inserted and fixed to the conjunctival tissue.
  • the groove formed on the lower surface of each of the plurality of fixing parts is widened. Since the body of the structure may be formed of collagen having elasticity as a whole, grooves may be opened when a slight pressure is applied with a finger. If the pressure is released after attaching the structure to the eyeball in this state, a part of the conjunctival tissue may be inserted into the flaring groove and the structure may be fixed to the eyeball.
  • the conjunctival tissue inserted into each groove may be a conjunctival tissue outside the lens. That is, it can be fixed at a position that does not affect the securing of the field of view.

Abstract

The disclosed technology relates to an eye treatment structure comprising: a drug delivery part, which has an oval lens shape, and is positioned above the eye surface of a wearer so as to deliver drug to the eyes; and a plurality of support parts, which are formed along the edge of the drug delivery part, maintain that the drug delivery part does not come in contact with the eyes because of bodies erected to a predetermined height, and are respectively fixed to the eyes by using grooves formed at the lower surfaces thereof.

Description

안구 치료용 구조체Structure for eye treatment
개시된 기술은 안구에 지속적으로 약물을 전달하기 위한 안구 치료용 구조체에 관한 것이다.The disclosed technology relates to an eye treatment structure for continuously delivering a drug to the eye.
각종 안질환이나 결막 손상과 같은 문제로 인해 안구에 약물을 투여해야 하는 환자들은 스포이드나 안약 용기를 이용하여 지속적으로 안구에 점안액과 같은 약물을 투여하고 있다. 그러나 눈물로 인해 투여한 약물의 농도가 낮아지고, 비루관 펌프(nasolacrimal pump)작용으로 인해 안구표면에 남아있는 비율이 적어서 여러번 반복 점안하는 번거로움이 있어서 이를 대체하기 위하여 약물에 담지된 렌즈나 안구 접착 형태의 구조체를 이용하고 있다.Patients who need to administer drugs to the eye due to problems such as various eye diseases or conjunctival damage are continuously administering drugs such as eye drops to the eye using an eyedropper or an eye drop container. However, since the concentration of the administered drug is lowered due to tears and the ratio remaining on the ocular surface is small due to the action of the nasolacrimal pump, it is inconvenient to repeat eye drops several times. I am using a struct of the form.
그러나, 종래의 구조체의 경우 안구의 표면에 직접 접착되는 방식으로 착용자의 시야를 가리거나 이물감이 느껴지는 등의 문제가 있었으며 장시간 사용 시 결막이 추가적으로 손상될 수 있는 문제가 있었다.However, in the case of the conventional structure, there are problems such as blocking the wearer's vision or feeling a foreign body in a way that is directly adhered to the surface of the eyeball, and there is a problem that the conjunctiva may be additionally damaged when used for a long time.
개시된 기술은 안구에 지속적으로 약물을 전달하기 위한 안구 치료용 구조체를 제공하는데 있다.The disclosed technology is to provide a structure for ocular treatment for continuously delivering a drug to the eye.
상기의 기술적 과제를 이루기 위하여 개시된 기술의 제 1 측면은 타원형의 렌즈 형상이고 착용자의 안구 표면에 위치하여 상기 안구에 약물을 전달하는 약물전달부 및 상기 약물전달부의 가장자리를 따라 형성되고 일정 높이로 세워진 몸체에 따라 상기 약물전달부가 상기 안구에 접촉되지 않게 유지하고 하면에 형성된 홈을 이용하여 상기 안구에 각각 고정되는 복수개의 지지부를 포함하는 안구 치료용 구조체를 제공하는데 있다.The first aspect of the technology disclosed to achieve the above technical problem is an elliptical lens shape and is located on the surface of the wearer's eyeball to deliver a drug to the eyeball and a drug delivery unit formed along the edge of the drug delivery unit and erected at a certain height An object of the present invention is to provide a structure for eye treatment including a plurality of support parts that keep the drug delivery unit from contacting the eyeball according to the body and are respectively fixed to the eyeball using grooves formed on the lower surface.
개시된 기술의 실시 예들은 다음의 장점들을 포함하는 효과를 가질 수 있다. 다만, 개시된 기술의 실시 예들이 이를 전부 포함하여야 한다는 의미는 아니므로, 개시된 기술의 권리범위는 이에 의하여 제한되는 것으로 이해되어서는 아니 될 것이다. Embodiments of the disclosed technology may have effects including the following advantages. However, this does not mean that the embodiments of the disclosed technology must include all of them, so the scope of rights of the disclosed technology should not be understood as being limited thereby.
개시된 기술의 일 실시예에 따른 안구 치료용 구조체는 안구 표면에서 일정 이상 이격된 위치에서 약물을 전달하여 이물감을 줄이는 효과가 있다.The structure for eye treatment according to an embodiment of the disclosed technology has an effect of reducing foreign body sensation by delivering a drug at a location spaced apart from the surface of the eye by a predetermined distance or more.
또한, 결막 조직을 홈에 끼워서 고정하는 방식으로 추가적인 조직 손상을 방지하는 효과가 있다.In addition, there is an effect of preventing additional tissue damage by fixing the conjunctival tissue by inserting it into the groove.
도 1은 개시된 기술의 일 실시예에 따른 안구 치료용 구조체를 나타낸 사시도이다.1 is a perspective view showing a structure for eye treatment according to an embodiment of the disclosed technology.
도 2는 중심이 개방된 형태의 안구 치료용 구조체를 나타낸 도면이다.2 is a view showing a structure for eye treatment in the form of an open center.
도 3은 평면 형태의 약물전달부를 나타낸 도면이다.3 is a view showing a drug delivery unit in a planar shape.
도 4는 곡면 형태의 약물전달부를 나타낸 도면이다.4 is a view showing a drug delivery unit in a curved shape.
도 5는 결막 조직에 끼워져서 고정되는 것을 나타낸 도면이다.5 is a view showing that it is inserted and fixed to the conjunctival tissue.
본 발명은 다양한 변경을 가할 수 있고 여러 가지 실시예를 가질 수 있는 바, 특정 실시예들을 도면에 예시하고 상세한 설명에 상세하게 설명하고자 한다. 그러나, 이는 본 발명을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변경, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다.Since the present invention can make various changes and have various embodiments, specific embodiments will be illustrated in the drawings and described in detail in the detailed description. However, this is not intended to limit the present invention to specific embodiments, and should be understood to include all modifications, equivalents, and substitutes included in the spirit and scope of the present invention.
제 1 , 제 2, A, B 등의 용어는 다양한 구성요소들을 설명하는데 사용될 수 있지만, 해당 구성요소들은 상기 용어들에 의해 한정되지는 않으며, 단지 하나의 구성요소를 다른 구성요소로부터 구별하는 목적으로만 사용된다. 예를 들어, 본 발명의 권리 범위를 벗어나지 않으면서 제 1 구성요소는 제 2 구성요소로 명명될 수 있고, 유사하게 제 2 구성요소도 제 1 구성요소로 명명될 수 있다. 및/또는 이라는 용어는 복수의 관련된 기재된 항목들의 조합 또는 복수의 관련된 기재된 항목들 중의 어느 항목을 포함한다.Terms such as first, second, A, B, etc. may be used to describe various components, but the components are not limited by the above terms, and are only used for the purpose of distinguishing one component from another. used only as For example, a first element may be termed a second element, and similarly, a second element may be termed a first element, without departing from the scope of the present invention. The terms and/or include any combination of a plurality of related recited items or any of a plurality of related recited items.
본 명세서에서 사용되는 용어에서 단수의 표현은 문맥상 명백하게 다르게 해석되지 않는 한 복수의 표현을 포함하는 것으로 이해되어야 한다. 그리고 "포함한다" 등의 용어는 설시된 특징, 개수, 단계, 동작, 구성요소, 부분품 또는 이들을 조합한 것이 존재함을 의미하는 것이지, 하나 또는 그 이상의 다른 특징들이나 개수, 단계 동작 구성요소, 부분품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 배제하지 않는 것으로 이해되어야 한다.In the terms used herein, singular expressions should be understood to include plural expressions unless the context clearly dictates otherwise. And the term "includes" means that the described feature, number, step, operation, component, part, or combination thereof exists, but one or more other features or number, step, operation component, or part. or the possibility of the presence or addition of combinations thereof.
도면에 대한 상세한 설명을 하기에 앞서, 본 명세서에서의 구성부들에 대한 구분은 각 구성부가 담당하는 주기능 별로 구분한 것에 불과함을 명확히 하고자 한다. 즉, 이하에서 설명할 2개 이상의 구성부가 하나의 구성부로 합쳐지거나 또는 하나의 구성부가 보다 세분화된 기능별로 2개 이상으로 분화되어 구비될 수도 있다. Prior to a detailed description of the drawings, it is to be clarified that the classification of components in the present specification is merely a classification for each main function in charge of each component. That is, two or more components to be described below may be combined into one component, or one component may be divided into two or more for each more subdivided function.
그리고 이하에서 설명할 구성부 각각은 자신이 담당하는 주기능 이외에도 다른 구성부가 담당하는 기능 중 일부 또는 전부의 기능을 추가적으로 수행할 수도 있으며, 구성부 각각이 담당하는 주기능 중 일부 기능이 다른 구성부에 의해 전담되어 수행될 수도 있음은 물론이다. 따라서, 본 명세서를 통해 설명되는 각 구성부들의 존재 여부는 기능적으로 해석되어야 할 것이다.In addition, each component to be described below may additionally perform some or all of the functions of other components in addition to its main function, and some of the main functions of each component may be performed by other components. Of course, it may be dedicated and performed by . Therefore, the existence or nonexistence of each component described through this specification should be interpreted functionally.
도 1은 개시된 기술의 일 실시예에 따른 안구 치료용 구조체를 나타낸 사시도이다. 도 1을 참조하면 안구 치료용 구조체는 약물전달부(110) 및 복수개의 지지부(120)를 포함한다.1 is a perspective view showing a structure for eye treatment according to an embodiment of the disclosed technology. Referring to FIG. 1 , the structure for eye treatment includes a drug delivery unit 110 and a plurality of support units 120 .
약물전달부(110)는 타원형의 렌즈 형상을 갖는다. 일반적으로 안구에 착용하는 렌즈와 같이 투명한 재질일 수 있다. 약물전달부는 착용자의 안구 표면에 위치하여 안구에 약물을 전달한다. 약물전달부는 착용자의 시야를 방해하지 않도록 중심이 개방된 구조일 수 있다. 예컨대, 도넛 모양과 같이 중심이 비어있을 수 있다.The drug delivery unit 110 has an oval lens shape. In general, it may be a transparent material like a lens worn on the eyeball. The drug delivery unit is located on the surface of the wearer's eyeball to deliver the drug to the eyeball. The drug delivery unit may have a structure with an open center so as not to obstruct the wearer's field of view. For example, the center may be empty like a donut shape.
한편, 안구에 약물을 전달하기 위해서 약물전달부는 약물이 혼입된 생체적합성 고분자 소재로 형성될 수 있다. 예컨대, 콜라겐과 같은 재질에 약물을 혼합하거나 재질의 외면에 약물을 도포한 상태로 형성될 수 있다. 이러한 약물전달부는 전기방사 방식으로 상술한 생체적합성 고분자 소재를 토출시키는 방식으로 형성될 수 있다.Meanwhile, in order to deliver the drug to the eye, the drug delivery unit may be formed of a biocompatible polymer material into which the drug is incorporated. For example, it may be formed in a state in which a drug is mixed with a material such as collagen or a drug is applied to the outer surface of the material. The drug delivery unit may be formed by discharging the above-described biocompatible polymeric material by electrospinning.
또한, 약물전달부(110)는 안구와 마주보는 면에 약물이 도포되어 약물이 형성하는 부착력 또는 접착력에 의해 약물전달부(110)가 안구의 형상에 상응하는 형상으로 곡면이 형성되며 부착될 수 있다. 약물전달부(110)는 안구와 직접적인 접촉은 없으나 약물을 통해 안구와 간접적으로 부착될 수 있다.In addition, in the drug delivery unit 110, a drug is applied to the surface facing the eyeball, and the drug delivery unit 110 is formed into a curved surface in a shape corresponding to the shape of the eyeball by the adhesive force formed by the drug, and can be attached thereto. there is. The drug delivery unit 110 does not directly contact the eye, but may be indirectly attached to the eye through the drug.
복수개의 지지부는 약물전달부의 가장자리를 따라 형성된다. 예컨대, 타원형 몸체로 형성되는 약물전달부의 가장자리에 복수개의 지지부가 일정 간격마다 형성될 수 있다. 각 지지부들의 간격은 서로 등간격일 수도 있고 사전에 정해진 위치에 형성될 수도 있다. 각 지지부들은 일정 높이로 세워진 몸체에 따라 약물전달부가 안구에 접촉되지 않게 유지할 수 있다. A plurality of support units are formed along the edge of the drug delivery unit. For example, a plurality of support units may be formed at regular intervals at the edge of the drug delivery unit formed in an elliptical body. The intervals of each support part may be equal intervals from each other or may be formed at predetermined positions. Each of the support parts can keep the drug delivery part from contacting the eyeball according to the body erected at a certain height.
종래 알티플렉스(Artiflex)와 같이 시각적 문제를 갖는 환자들이 착용하는 렌즈 형태의 구조체의 경우 몸체가 안구 표면에 밀착되어 결막에 추가적인 손상이 발생하거나 눈에 이물감이 심해지는 문제가 있었다. 이러한 문제점을 해소하기 위해서 개시된 기술에 따른 약물 전달용 구조체는 복수개의 지지부들의 몸체가 약물전달부에 수직 방향으로 세워져 있어서 약물전달부와 안구 표면이 일정 간격 떨어진 상태를 유지할 수 있다. 이에 따라 안구에 이물감이 느껴지지 않고 지속적으로 동일한 양의 약물에 안구를 노출시킬 수 있어서 장시간 이용시에도 큰 불편함 없이 이용할 수 있다.In the case of a lens-shaped structure worn by patients with visual problems, such as the conventional Artiflex, the body is in close contact with the surface of the eyeball, causing additional damage to the conjunctiva or worsening the foreign body sensation in the eye. In order to solve this problem, in the structure for drug delivery according to the disclosed technology, the bodies of the plurality of supporters are erected in a vertical direction to the drug delivery unit, so that the drug delivery unit and the surface of the eyeball can be maintained at a predetermined interval. Accordingly, the eyeball can be continuously exposed to the same amount of drug without feeling a foreign body sensation, so that the eyeball can be used without great discomfort even when used for a long time.
한편, 복수개의 지지부 각각의 하면에는 홈(120a)이 형성되어 있다. 종래 안구 치료용 구조체의 경우 안구 일 측이나 결막 자체에 봉합하여 고정시키는 방식이어서 추가적인 결막 손상이 발생할 수 있는데 개시된 기술에서는 홈에 압력을 가하여 벌어지게 한 뒤 벌어진 홈으로 결막 조직이 끼워지게 하여 고정시키는 방식이어서 추가적인 결막 손상도 발생하지 않는 장점이 있다.Meanwhile, a groove 120a is formed on the lower surface of each of the plurality of support parts. In the case of a structure for conventional eye treatment, it is a method of fixing by suturing to one side of the eyeball or the conjunctiva itself, so additional conjunctival damage may occur. This method has the advantage of not causing additional conjunctival damage.
도 2는 중심이 개방된 형태의 안구 치료용 구조체를 나타낸 도면이다. 도 2를 참조하면 착용자의 시야를 방해하지 않도록 약물전달부의 몸체 중심부의 공간(201)이 비어있는 구조를 가질 수 있다. 즉, 착용 시 시야를 확보하게 되어 불편함을 더욱 줄이는 것이 가능하다. 추가적으로 비어있는 공간을 통해 점안액과 같은 약물을 추가적으로 투여하는 것 또한 가능하다. 이 경우 종래와 같이 약물이 밖으로 흐르는 것을 방지할 수 있다.2 is a view showing a structure for eye treatment in the form of an open center. Referring to FIG. 2 , the space 201 at the center of the body of the drug delivery unit may have an empty structure so as not to obstruct the wearer's vision. That is, it is possible to further reduce discomfort by securing a field of view when worn. It is also possible to additionally administer a drug such as eye drops through an additionally empty space. In this case, as in the prior art, it is possible to prevent the drug from flowing out.
도 3은 평면 형태의 약물전달부를 나타낸 도면이다. 그리고 도 4는 곡면 형태의 약물전달부를 나타낸 도면이다. 약물전달부는 사용자의 니즈나 안구 상태에 따라 표면이 평면 형태일 수도 있고 종래 렌즈와 같이 곡면 형태일 수도 있다.3 is a view showing a drug delivery unit in a planar shape. And Figure 4 is a view showing a drug delivery unit in the form of a curved surface. The drug delivery unit may have a flat surface or a curved surface like a conventional lens, depending on the user's needs or eye conditions.
도 5는 결막 조직에 끼워져서 고정되는 것을 나타낸 도면이다. 도 5에 도시된 화살표 방향으로 압력을 가하게 되면 복수개의 고정부 각각의 하면에 형성된 홈이 벌어지게 된다. 구조체의 몸체는 전체적으로 탄성을 갖는 콜라겐으로 형성될 수 있으므로 손가락으로 약간의 압력을 가하게 되면 홈이 벌어질 수 있다. 이 상태로 안구에 부착시킨 뒤 압력을 해제하면 벌어짐 홈에 결막 조직의 일부가 끼워지면서 구조체가 안구에 고정될 수 있다.5 is a view showing that it is inserted and fixed to the conjunctival tissue. When pressure is applied in the direction of the arrow shown in FIG. 5, the groove formed on the lower surface of each of the plurality of fixing parts is widened. Since the body of the structure may be formed of collagen having elasticity as a whole, grooves may be opened when a slight pressure is applied with a finger. If the pressure is released after attaching the structure to the eyeball in this state, a part of the conjunctival tissue may be inserted into the flaring groove and the structure may be fixed to the eyeball.
여기에서 각각의 홈에 끼워지는 결막 조직은 수정체 바깥쪽의 결막 조직일 수 있다. 즉, 시야 확보에 영향을 주지 않는 위치에 고정될 수 있다.Here, the conjunctival tissue inserted into each groove may be a conjunctival tissue outside the lens. That is, it can be fixed at a position that does not affect the securing of the field of view.
개시된 기술의 일 실시예에 따른 안구 치료용 구조체는 이해를 돕기 위하여 도면에 도시된 실시 예를 참고로 설명되었으나, 이는 예시적인 것에 불과하며, 당해 분야에서 통상적 지식을 가진 자라면 이로부터 다양한 변형 및 균등한 타 실시 예가 가능하다는 점을 이해할 것이다. 따라서, 개시된 기술의 진정한 기술적 보호범위는 첨부된 특허청구범위에 의해 정해져야 할 것이다.The structure for eye treatment according to an embodiment of the disclosed technology has been described with reference to the embodiment shown in the drawings to aid understanding, but this is only an example, and those skilled in the art can make various modifications and It will be appreciated that other equivalent embodiments are possible. Therefore, the true technical protection scope of the disclosed technology should be defined by the appended claims.

Claims (4)

  1. 타원형의 렌즈 형상이고 착용자의 안구 표면에 위치하여 상기 안구에 약물을 전달하는 약물전달부; 및a drug delivery unit having an elliptical lens shape and located on the surface of the wearer's eyeball to deliver the drug to the eyeball; and
    상기 약물전달부의 가장자리를 따라 형성되고 일정 높이로 세워진 몸체에 따라 상기 약물전달부가 상기 안구에 접촉되지 않게 유지하고 하면에 형성된 홈을 이용하여 상기 안구에 각각 고정되는 복수개의 지지부;를 포함하는 안구 치료용 구조체.Eye treatment comprising: a plurality of support parts formed along the edge of the drug delivery part and holding the drug delivery part so as not to come into contact with the eyeball according to the body erected at a certain height and fixed to the eyeball using grooves formed on the lower surface thereof. dragon structure.
  2. 제 1 항에 있어서,According to claim 1,
    상기 약물전달부는 상기 착용자의 시야를 방해하지 않도록 중심이 개방된 구조인 안구 치료용 구조체.The structure for eye treatment, wherein the drug delivery unit has a structure in which the center is open so as not to interfere with the wearer's field of view.
  3. 제 1 항에 있어서,According to claim 1,
    상기 약물전달부는 약물이 혼입된 생체적합성 고분자 소재를 전기방사 방식으로 토출하여 형성되는 안구 치료용 구조체.An eye treatment structure formed by discharging a biocompatible polymeric material into which the drug delivery unit is incorporated in an electrospinning manner.
  4. 제 1 항에 있어서,According to claim 1,
    상기 지지부는 착용 시 가해지는 압력에 따라 상기 홈이 벌어지면 상기 안구의 결막 조직의 일부가 상기 홈에 끼워져서 상기 안구에 고정되는 안구 치료용 구조체.When the groove is widened according to the pressure applied when the support is worn, a part of the conjunctival tissue of the eyeball is fitted into the groove and fixed to the eyeball.
PCT/KR2022/009708 2021-07-21 2022-07-06 Eye treatment structure WO2023003223A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020210095673A KR102622048B1 (en) 2021-07-21 2021-07-21 Structure for eye treatment
KR10-2021-0095673 2021-07-21

Publications (1)

Publication Number Publication Date
WO2023003223A1 true WO2023003223A1 (en) 2023-01-26

Family

ID=84979417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/009708 WO2023003223A1 (en) 2021-07-21 2022-07-06 Eye treatment structure

Country Status (2)

Country Link
KR (1) KR102622048B1 (en)
WO (1) WO2023003223A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58203752A (en) * 1981-12-17 1983-11-28 フレツド・トマソン・フエスタ− Endoophthalmic implant lens
US20140323995A1 (en) * 2013-04-24 2014-10-30 Transcend Medical, Inc. Targeted Drug Delivery Devices and Methods
US20150077701A1 (en) * 2013-06-26 2015-03-19 Nexisvision, Inc. Contact lenses for refractive correction
KR20180057320A (en) * 2016-11-22 2018-05-30 한국과학기술연구원 Contact lens for collecting tear or delivering drug, and Method for manufacturing the contact lens
KR20210017317A (en) * 2019-08-07 2021-02-17 김대윤 Support Structure for Artificial Eyes Lens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7806930B2 (en) * 2004-08-27 2010-10-05 Brown David C Device for attachment to a capsule in an eye
CA2834295A1 (en) * 2011-04-28 2012-11-01 Nexisvision, Inc. Eye covering and refractive correction methods and apparatus having improved tear flow, comfort, and/or applicability
EP3291886A1 (en) * 2015-05-04 2018-03-14 Ecole Polytechnique Federale de Lausanne (EPFL) Ophthalmic contact lens with a compressible affinity matrix
KR101877031B1 (en) 2016-12-30 2018-07-11 주식회사 윈스 drug-loaded contact lens
JP6501096B1 (en) 2018-03-30 2019-04-17 真一 芦田 Drug supply eye equipment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58203752A (en) * 1981-12-17 1983-11-28 フレツド・トマソン・フエスタ− Endoophthalmic implant lens
US20140323995A1 (en) * 2013-04-24 2014-10-30 Transcend Medical, Inc. Targeted Drug Delivery Devices and Methods
US20150077701A1 (en) * 2013-06-26 2015-03-19 Nexisvision, Inc. Contact lenses for refractive correction
KR20180057320A (en) * 2016-11-22 2018-05-30 한국과학기술연구원 Contact lens for collecting tear or delivering drug, and Method for manufacturing the contact lens
KR20210017317A (en) * 2019-08-07 2021-02-17 김대윤 Support Structure for Artificial Eyes Lens

Also Published As

Publication number Publication date
KR102622048B1 (en) 2024-01-05
KR20230014388A (en) 2023-01-30
KR102622048B9 (en) 2024-04-08

Similar Documents

Publication Publication Date Title
WO2014069881A1 (en) Therapeutic contact lens
US8216603B2 (en) Method, device, and system for delivery of therapeutic agents to the eye
US20200315846A1 (en) Glaucoma treatment devices and methods
Pereira et al. Conventional glaucoma implants and the new MIGS devices: a comprehensive review of current options and future directions
US5472436A (en) Ocular appliance for delivering medication
CN1203814C (en) Opthalmic drug delivery device
US20210220172A1 (en) Dry eye treatment devices and methods
AU2014241163B2 (en) Ophthalmic implant for delivering therapeutic substances
US20100189766A1 (en) Substance delivering punctum implants and methods
KR20140061520A (en) Ocular insert apparatus and methods
BRPI1007318A2 (en) sustained release distribution of one or more agents.
JP2004535886A (en) Eye drug delivery device
EP3092983B1 (en) Trans-sclera portal for delivery of therapeutic agents
WO2016195143A1 (en) Intraocular lens assembly
Ayyala et al. Glaucoma drainage devices: state of the art
US20180271643A1 (en) Optic nerve support implant
WO2023003223A1 (en) Eye treatment structure
CN218842014U (en) Corneal contact lens with medicine slow-release function
WO2014058205A1 (en) Pinhole contact lens in which symmetrical light quantity reinforcement unit is formed
CN204016558U (en) Modified model artificial intraocular lenses
CN112790911A (en) Glaucoma drainage device
CN214967571U (en) Eye medicine applying device
ES2926281T3 (en) Ophthalmic surgery device
WO2020190086A2 (en) Artificial eye aid and artificial eye assembly provided with same
US20210023165A1 (en) Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22846095

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE